We have recently described corin, a potent and specific dual-warhead inhibitor of the CoREST complex targeting HDAC1/2 and LSD1, that demonstrates growth inhibition in melanoma (16), cutaneous squamous cell carcinoma (16), breast cancers (17), and diffuse intrinsic pontine glioma (18). This evidence concerns the gene RCOR1 and breast cancer.